Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TransCode TherapeuticsRNAZ -7.26%34 Equity-to-Asset is 0.92 as of Mar. 2026, which is 114% above its 10-year median of 0.43. GuruFocus rates RNAZ with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,413 Biotechnology companies, TransCode Therapeutics ranks better than 87.62% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
TransCode Therapeutics Equity-to-Asset Related Terms
TransCode Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for TransCode Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RNAZ vs BCAB, APVO, SNGX: Equity-to-Asset Comparison
For the Biotechnology subindustry, TransCode Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransCode Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where TransCode Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
TransCode Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransCode Therapeutics (RNAZ) has a Equity-to-Asset of 0.92 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on TransCode Therapeutics and its competitors. This is 114% above median its historical median of 0.43. According to the industry distribution chart, TransCode Therapeutics ranks #175 out of 1413 companies in the Biotechnology industry, placing it in the top 12.4%.
Is TransCode Therapeutics' Equity-to-Asset too high?
TransCode Therapeutics' current Equity-to-Asset of 0.92 is 114% above median its 10-year median of 0.43. The Biotechnology industry median Equity-to-Asset is 0.68. TransCode Therapeutics' value of 0.92 is 35.3% above this industry median. Based on the distribution chart, TransCode Therapeutics ranks #175 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TransCode Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' Equity-to-Asset compare to BCAB and APVO?
According to the Biotechnology industry distribution chart, TransCode Therapeutics ranks #175 out of 1413 companies for Equity-to-Asset. This places TransCode Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. TransCode Therapeutics' value of 0.92 is 35.3% above this benchmark. While the company's 10-year median is 0.43 vs. the industry median of 0.68, TransCode Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransCode Therapeutics's current Equity-to-Asset of 0.92 is 35.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on TransCode Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransCode Therapeutics's current Equity-to-Asset is 0.92, which is 114% above median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current Equity-to-Asset of 0.92. The current Equity-to-Asset is 0.92, which is 114% above median its 10-year median of 0.43 and 35.3% above the Biotechnology industry median of 0.68. TransCode Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current Equity-to-Asset is 0.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
34GF Score
Get the complete analysis for RNAZ
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNAZ has been successfully added to your 
